CR20210670A - Inhibidores aza-heterobicíclicos de mat2a y métodos de uso para tratar el cáncer - Google Patents

Inhibidores aza-heterobicíclicos de mat2a y métodos de uso para tratar el cáncer

Info

Publication number
CR20210670A
CR20210670A CR20210670A CR20210670A CR20210670A CR 20210670 A CR20210670 A CR 20210670A CR 20210670 A CR20210670 A CR 20210670A CR 20210670 A CR20210670 A CR 20210670A CR 20210670 A CR20210670 A CR 20210670A
Authority
CR
Costa Rica
Prior art keywords
mat2a
methods
treating cancer
inhibitors
compounds
Prior art date
Application number
CR20210670A
Other languages
English (en)
Inventor
Mingzong Li
Zhihua Sui
Zenon D Konteatis
Jeremy M Travins
Samuel K Reznik
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of CR20210670A publication Critical patent/CR20210670A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente descripción proporciona compuestos de acuerdo con la Fórmula I, Fórmula II, y sus sales, tautómeros y/o isotopólogos farmacéuticamente aceptables como se describe en la descripción. Los compuestos son inhibidores de la metionina adenosiltransferasa isoforma 2A (MAT2A). También se proporcionan composiciones farmacéuticas y métodos para usar los compuestos para el tratamiento del cáncer, incluidos algunos cánceres en los que se elimina el gen que codifica la metiltioadenosina fosforilasa (MTAP).
CR20210670A 2019-05-31 2020-05-29 Inhibidores aza-heterobicíclicos de mat2a y métodos de uso para tratar el cáncer CR20210670A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962855395P 2019-05-31 2019-05-31
PCT/US2020/035036 WO2020243376A1 (en) 2019-05-31 2020-05-29 Heterobicyclic inhibitors of mat2a and methods of use for treating cancer

Publications (1)

Publication Number Publication Date
CR20210670A true CR20210670A (es) 2022-02-11

Family

ID=72179154

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210670A CR20210670A (es) 2019-05-31 2020-05-29 Inhibidores aza-heterobicíclicos de mat2a y métodos de uso para tratar el cáncer

Country Status (16)

Country Link
US (1) US20220251081A1 (es)
EP (1) EP3976611A1 (es)
JP (1) JP2022534989A (es)
AR (1) AR119046A1 (es)
AU (1) AU2020284018A1 (es)
BR (1) BR112021023825A2 (es)
CA (1) CA3142340A1 (es)
CO (1) CO2021017981A2 (es)
CR (1) CR20210670A (es)
IL (1) IL288395A (es)
JO (1) JOP20210317A1 (es)
MA (1) MA56050A (es)
PE (1) PE20220387A1 (es)
SG (1) SG11202112952SA (es)
TW (1) TW202110841A (es)
WO (1) WO2020243376A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12077534B2 (en) * 2018-12-27 2024-09-03 Les Laboratoires Servier Aza-heterobicyclic inhibitors of MAT2A and methods of use for treating cancer
CN115960098B (zh) * 2020-09-11 2026-04-10 上海凌达生物医药有限公司 一类含氮稠环类化合物的制备方法和用途
CN115960099A (zh) * 2020-09-24 2023-04-14 上海凌达生物医药有限公司 一类芳环或芳基杂环并吡啶酮类化合物、药物组合物及其应用
CN114507231B (zh) * 2020-11-17 2025-06-03 南京再明医药有限公司 内酰胺类化合物及其制备方法
PE20231311A1 (es) 2020-11-18 2023-08-24 Deciphera Pharmaceuticals Llc Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos
WO2022143864A1 (zh) * 2020-12-31 2022-07-07 江苏先声药业有限公司 三环类化合物及用途
CN114874207A (zh) * 2021-02-05 2022-08-09 江苏先声药业有限公司 作为mat2a抑制剂的双环类化合物
CN115141202A (zh) * 2021-03-29 2022-10-04 武汉人福创新药物研发中心有限公司 嘧啶并吡嗪酮化合物及其用途
CN117295734A (zh) * 2021-04-30 2023-12-26 赛诺哈勃药业（成都）有限公司 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用
EP4385978A4 (en) * 2021-08-12 2025-08-13 Tyk Medicines Inc POLYCYCLIC COMPOUND AND ITS USE
CN118434722A (zh) 2021-10-20 2024-08-02 英矽智能科技知识产权有限公司 甲硫氨酸腺苷转移酶2a(mat2a)抑制剂及其用途
CN118265700A (zh) * 2021-11-09 2024-06-28 上海海雁医药科技有限公司 取代的萘啶酮衍生物、其药物组合物及应用
MX2024006627A (es) 2021-12-03 2024-08-22 Deciphera Pharmaceuticals Llc Inhibidores de gcn2 y perk quinasa y metodos de uso de los mismos.
CN118414338A (zh) * 2021-12-21 2024-07-30 南京正大天晴制药有限公司 蛋氨酸腺苷转移酶2a的杂环抑制剂
KR20240138099A (ko) * 2022-01-26 2024-09-20 쑤저우 젠하우스 바이오 컴퍼니 리미티드 Mtap 결실 암을 치료하기 위한 메티오닌 아데노실트랜스퍼라제 2a 억제제
CN118742550B (zh) * 2022-03-11 2025-09-05 赛诺哈勃药业（成都）有限公司 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用
AU2023299635A1 (en) 2022-06-27 2025-01-02 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd Tricyclic compounds and uses thereof
CN117430596A (zh) * 2022-07-13 2024-01-23 上海海和药物研究开发股份有限公司 二并环类mat2a抑制剂及其用途
EP4582423A1 (en) * 2022-10-13 2025-07-09 Hanmi Pharm. Co., Ltd. Novel tricyclic derivative compound and uses thereof
WO2024107730A1 (en) * 2022-11-14 2024-05-23 Onconova Therapeutics, Inc. Methods and compositions for treating cancer
CN117645598A (zh) * 2023-02-16 2024-03-05 武汉誉祥医药科技有限公司 氮杂二并多元稠环化合物及其药物组合物和应用
CN116239541B (zh) * 2023-05-11 2023-07-21 英矽智能科技(上海)有限公司 N-苯基-2-氧代喹唑啉类化合物及其应用
WO2024255802A1 (zh) * 2023-06-14 2024-12-19 南京正大天晴制药有限公司 蛋氨酸腺苷转移酶2a杂环抑制剂的盐、晶型及其制备方法
WO2025152991A1 (zh) * 2024-01-15 2025-07-24 江苏威凯尔医药科技股份有限公司 一种mat2a抑制剂及其用途
WO2025162209A1 (zh) * 2024-02-01 2025-08-07 艾立康药业股份有限公司 一种吡啶并吡啶酮类mat2a抑制剂及其药物组合物、医药用途
CN118724899B (zh) * 2024-07-03 2025-09-30 中国药科大学 2(1h)-喹喔啉酮化合物、其药物组合物及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576420B1 (en) 1998-06-23 2003-06-10 Regents Of The University Of California Method for early diagnosis of, and determination of prognosis in, cancer
KR100571339B1 (ko) * 2000-08-31 2006-04-17 에프. 호프만-라 로슈 아게 세포증식 억제제로서의 7-옥소 피리도피리미딘
US7098332B2 (en) * 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
WO2008078249A1 (en) * 2006-12-21 2008-07-03 Ranbaxy Laboratories Limited Anti-inflammatory agents
US8367706B2 (en) 2007-06-20 2013-02-05 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
HUE066282T2 (hu) * 2018-03-30 2024-07-28 Servier Lab Heterobiciklusos MAT2A-gátlók és eljárások rák kezelésében történõ alkalmazásukra

Also Published As

Publication number Publication date
JOP20210317A1 (ar) 2023-01-30
MA56050A (fr) 2022-04-06
CO2021017981A2 (es) 2022-04-19
PE20220387A1 (es) 2022-03-18
JP2022534989A (ja) 2022-08-04
CA3142340A1 (en) 2020-12-03
BR112021023825A2 (pt) 2022-02-08
US20220251081A1 (en) 2022-08-11
EP3976611A1 (en) 2022-04-06
WO2020243376A1 (en) 2020-12-03
AU2020284018A1 (en) 2022-01-27
IL288395A (en) 2022-01-01
AR119046A1 (es) 2021-11-17
SG11202112952SA (en) 2021-12-30
TW202110841A (zh) 2021-03-16

Similar Documents

Publication Publication Date Title
JOP20210317A1 (ar) مثبطات غير متجانسة ثنائية الحلقة لـ mat2a وطرق استخدامها لعلاج السرطان
SA521422405B1 (ar) Mat2a مثبطات أزا-غير متجانسة ثنائية الحلقة لـ وطرق الاستخدام لعلاج السرطان
PH12021551493A1 (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
PH12020551507A1 (en) Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
PH12021551274A1 (en) 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
ZA202102999B (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX2023004802A (es) Compuestos espiro heterocíclicos y métodos de uso.
EP4552631A3 (en) Combination of dasatinib and adagrasib for use in the treatment of non-small cell lung cancer
PH12020552148A1 (en) Purinone compounds and their use in treating cancer
CR20200441A (es) Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
MX2020012376A (es) Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
PH12022550470A1 (en) Triazolopyrimidines as a2a / a2b inhibitors
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
MX2023003516A (es) Inhibidores no covalentes de la cinasa dependiente de ciclina 7 (cdk7).
MX2023000438A (es) Eter macrociclico que contiene derivados de indol como inhibidores de mcl-1.
MX2025002407A (es) Inhibidores de egfr y sus usos
ZA202005603B (en) Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
MX2023007291A (es) Derivados de 4-(pirazol-5-il)-indol macrociclicos ramificados como inhibidores de mcl-1.